STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Electro Optical Sciences — IPO Roadshow (July 2008)

42 slides from STRATA Skin Sciences's IPO roadshow presentation, Jul 28, 2008

  1. Slide 1: Needham & Co. 7th Annual Bio/MedTech Conference

    Needham & Co. 7 th Annual Bio/MedTech Conference June 11, 2008

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as “e

  3. Slide 3: Why Melanoma?

    Why Melanoma? · Melanoma kills 1 US citizen per hour · 80% of all skin cancer deaths · 50% increase in mortality since 1973 · Fastest growing cancer 6% per year · Most common cancer in women 25-29 · #1 cancer killer in women 30-35 · Affects all age groups · No cure for late stage disease...must diag

  4. Slide 4: Impact of Melanoma Mortality vs Other Cancers

    Impact of Melanoma Mortality vs Other Cancers Due to early age of diagnosis and lack of treatments that extend survival, the impact of malignant melanoma on average years of life lost (AYLL) and lifetime earnings lost (LEL) is greater than that of other cancers assessed. Average Years of Lifetime Ea

  5. Slide 5: Early Detection of Melanoma is the Only Hope for Cure

    Early Detection of Melanoma is the Only Hope for Cure Melanoma in situ 1.0 < 1 Stage I (n=9175) 0.8 mm 0.6 Stage II (n=5739) Proportion Surviving 0.4 Stage III (n=1528) 0.2 Stage IV (n=1158) 0.0 0 2 4 6 8 10 12 14 Survival (Years) Source: SEER (Surveillance, Epidemiology, and End Results) 5

  6. Slide 6: Melanoma in situ

    Melanoma in situ 4 mm – Left lower leg 10 years Post-M-plasty 30 year old woman procedure

  7. Slide 7: Stage II invasive melanoma

    Stage II invasive melanoma 2 years post 70 year old female Split-thickness skin graft 2 weeks post

  8. Slide 8: Stage III Melanoma

    Stage III Melanoma Stage IIIb — micrometastases Stage IIIb – satellite metastases

  9. Slide 9: Challenges Detecting Melanoma

    Challenges Detecting Melanoma < 1 mm VISUAL inspection – subjective A B C D E ? “ugly duckling” Can look like benign lesions Dermatology residence ~ 12 early stage melanomas seen Must biopsy to confirm suspicious Pick the right ones Experts miss 29% of small early stage melanomas 50 to 100 false pos

  10. Slide 10: Biopsies

    Biopsies Dysplastic nevus syndrome – painful hypertrophic scars following excisional biopsies 4-6 weeks hence

  11. Slide 11: Biopsies to Rule-Out Melanoma

    Biopsies to Rule-Out Melanoma Hypo-pigmented scars from saucerization biopsies to rule-out melanoma

  12. Slide 12: The MelaFind System

    The MelaFind ® System

  13. Slide 13: Spectrum of Light

    Spectrum of Light Increasing Energy Increasing Wavelength GAMMA XRAYS UV INFRARED RADIO WAVES VISIBLE LIGHT 400 500 600 700 800 900 Wavelengths utilized by MelaFind 430 470 500 550 600 660 700 770 880 950

  14. Slide 14: Multiple Depths

    Multiple Depths MelaFind reach 2.5 mm 1. Sees in 10 wavelengths including 3. Developed, trained, tested on infra-red 500 melanomas 2. Discerns 500 characteristics per 4. Completely OBJECTIVE wavelength = 5,000 features

  15. Slide 15: Visual Identification

    Visual Identification Asymmetry • Border Irregularity • Color Variegation • Diameter > 6mm 17

  16. Slide 16: Visual Identification

    Visual Identification COs en |

  17. Slide 17: MelaFind Phase Data – Interim System

    MelaFind ® Phase 2 Data – Interim System* Study 1 N = 352 PSLs 28 melanomas Experts MelaFind Specificity 28.4% 48.4% p < 0.0001 Over-Biopsy 7.9 : 1 5.7 : 1 Ratio Missed MelaFind detected Melanomas 28/28 melanomas * Software & algorithm development estimated to be 65% complete

  18. Slide 18: Dermatologist Sensitivity?

    Dermatologist Sensitivity? · 49 melanomas and 50 benign lesions matched by age, sex, and body location · 10 expert dermoscopists · Median size = 4.55 mm · 21/49 = invasive melanoma (0.32 mm Breslow thickness) · 28/49 = in situ melanoma · Experts identified 35/49 melanomas · MelaFind identified 48/49

  19. Slide 19: Reader Studies

    Reader Studies Foot — 13 year old boy 9/9 experts said no biopsy Front thigh – 43 yr old woman MelaFind said biopsy 9/9 experts said biopsy Pathology – melanoma in situ MelaFind said no biopsy Pathology – not melanoma (low grade nevus) Experts missed 29% of melanomas Archives Derm, May ‘08 Face — 12

  20. Slide 20: Pivotal Trial Methods / Design

    Pivotal Trial Methods / Design Blinded study in patients undergoing biopsy of pigmented skin lesions 7 clinical sites in US Accrue until 93 melanomas; > 1,200 lesions Central dermatohistopath reference standard Clinical & dermoscopic pictures with standard cameras MelaFind Pivotal Trial Endpoints –

  21. Slide 21: MelaFind Clinical Trials Accrual

    MelaFind Clinical Trials Accrual Simultaneous Trials using Commercial Hand-held Units (last 18 months – 14 sites) Classifier Training Studies Pivotal Trial – US only (US, Europe, Australia) (7 sites) > 100 melanomas > 60 melanomas > 85/93 eligible & evaluable > 600 lesions (e+e) melanomas for > 450

  22. Slide 22: MelaFind Pre-PMA FDA Interactions

    MelaFind Pre-PMA FDA Interactions Pre-PMA Discussions with FDA – May 2008 · Accept PMA Outline · Agree with filing approach (traditional vs modular PMA) · Provided requirements for data presentation A have been incorporated in our Statistical Analysis Plan · Begun discussions of Panel Composition FD

  23. Slide 23: Busy 2H08...

    Busy 2H08... · Auditing/closing of pivotal trial sites · Classifier Training, Testing, & Selection · Internet Readers Study: Ongoing / a. 90 physicians (dermatologists & PCPs) 3Q08 b. 130 lesions from the pivotal trial c. Principal Investigator d. Largest trial of its type · Software Quality System

  24. Slide 24: Commercialization Strategy – US Dermatologists

    Commercialization Strategy – US Dermatologists Dermatologist A Physician Extender A Dermatologist Physician Extender Dermatologist 1. Images lesions with MelaFind Dermatologist 1. Visual skin 2. Preps for 1. Reviews exam biopsy MelaFind results 2. Determines 2. Biopsies lesions lesions to image vs.

  25. Slide 25: Quantitative Research

    Quantitative Research 50% 46% Respondents 40% 180 dermatologists 30% 22% How many biopsies do you 19% 20% typically perform per 10% 5% 4% patient, per examination? % of 3% 81% perform 0% 1 2 3 4 5 more than multiple biopsies per 5 patient # of Biopsies per Patient Expected financial return 80% 70% P

  26. Slide 26: Quantitative Market Research – dermatologists

    Quantitative Market Research – 180 dermatologists On what patient types might you use a product like MelaFind? Those w ith atypical, iffy lesions — suspicious, but 90% don’t feel compelled to take them off. Those w ith moles that may have changed. 80% 70% Those w ith a family history or other high-r

  27. Slide 27: Burden of Biopsy Market Research

    Burden of Biopsy Market Research (n=53 staff) 90% 80% Average time by 1st bx 2nd bx 80% all caregivers 70% ($ 76-$90) (+$46-$60) 60% 50% Shave biopsy 0:40:00 0:43:39 40% 30% 20% % of Respondents 20% Punch biopsy 0:43:22 0:48:43 10% 0% Excisional biopsy 0:51:33 1:02:59 Yes No Would Perform Less Biops

  28. Slide 28: MelaFind Economics – reduced biopsies

    MelaFind Economics – reduced biopsies Revenue without MelaFind: Revenue with MelaFind: 20 pts biopsied/wk: $2,700 6 pts biopsied/wk: $800 Other procedures with biopsy time saved: $1,600 40 pts MelaFind/wk: $2,000 MelaFind operator: ($800) TOTAL/wk: $2,700 TOTAL/wk: $3,600 TOTAL/yr: $135,000 TOTAL/yr

  29. Slide 29: Practice Growth Opportunities

    Practice Growth Opportunities Increase revenue by offering other services to Consumer NEW patients Programs Drive NEW patients to derm offices for additional MelaFind exams Physician Programs Improve practice efficiency and re-allocate physician time for higher revenue services Physician Staff Patie

  30. Slide 30: Consumer/Patient Qualitative Feedback

    Consumer/Patient Qualitative Feedback “You hear so much about skin cancer these days... but the way doctors look at the skin is rather primitive and not an exact science.” “The best trained dermatologist’s eyes cannot go below skin surface but MelaFind can – why take a chance on cancer?” “ MelaFind

  31. Slide 31: Consumer Quantitative Market Research

    Consumer Quantitative Market Research – I n = 403 Patients “Melanoma Concerned” “Skin Care Involved” Skin Extremely concerned with Regular use of Awareness melanoma a/o prior cosmeceutical products & experience with melanoma procedures (Botox, fillers, (self or family/friend) laser, peels, etc.) N;

  32. Slide 32: Financial Summary

    Financial Summary Recent Financing History I.P.O. November 2005 $21,311,500 $5.00 / share PIPE November 2006 $13,180,590 $5.70 / share PIPE August 2007 $11,501,023 $5.75/ share Cash Position March 31, 2008 $17.2 million Shares Outstanding December 31, 2007 15,401,882 Warrants & Options 2,938,970 Tot

  33. Slide 33: Summary

    Summary Market for melanoma detection is large and growing Unmet medical need MelaFind ® is a breakthrough product for early detection Strong clinical trial results (>5,000 patients studied) FDA Protocol Agreement & Expedited Review 9 Pivotal trial accrual completion imminent 9 Pre-PMA discussions c

  34. Slide 34: Figure 1. Multispectral images for a melanoma in situ

    Figure 1. A sequence of multispectral images for a melanoma in situ, together with the automatically obtained segmentation mask for this sequence. inclusion in the ABCD rules. The asymmetry parameter, shown in Figure 9, was computed as follows. 12 First, in each spectral band the two orthogonal prin

  35. Slide 35: Figure 14.1 Current MelaFind System

    5 Figure 14.1 Current MelaFind ® System: (a) Probe and laptop computer in carrying case. (b) Hand-held MF-100/100A probe applied to a pigmented skin lesion

  36. Slide 36: Figure 14.2 MF-100 printed circuit board

    5 Figure 14.2 MF-100 printed circuit board with attached, angled-in light-emitting diodes ATLAS OF DERMOSCOPY

  37. Slide 37: Figure 14.3 Multispectral ten-image sequence

    5 Figure 14.3 A MelaFind ® multispectral ten-image sequence (for an invasive melanoma) and the automatically generated segmentation mask for this sequence AUTOMATED DIAGNOSIS: ILLUSTRATED BY THE MELAFIND ® SYSTEM

  38. Slide 38: Figure 14.4 Supervised learning approach

    5 Figure 14.4 ‘Supervised learning’ approach to development of quality control software

  39. Slide 39: Figure 14.5 Bubble-detection algorithm

    5 Figure 14.5 Example of the bubble-detection algorithm at work. (a) Rejected lesion image. (b) The bubbles detected in image (a). (c) Accepted lesion image.(d) Bubble-detection result for image (c) ATLAS OF DERMOSCOPY

  40. Slide 40: Figure 14.7 Lesion segmentation with hair

    5 Figure 14.7 Illustration of lesion segmentation in the presence of residual hair. (a) Original skin image. (b) Invalid lesion mask, generated without hair removal. (c) Hair mask. (d) Lesion segmentation mask, generated with hair removal AUTOMATED DIAGNOSIS: ILLUSTRATED BY THE MELAFIND ® SYSTEM

  41. Slide 41: Figure 14.8 MelaFind image and wavelet transformation

    5 Figure 14.8 Illustration of a MelaFind ® image and its wavelet transformation. (a) MelaFind dermoscopic gray-scale image of a melanoma at 430 nm (blue). (b) Pseudocolor representation of Wavelet transformation of the image in part (a)

  42. Slide 42: Figure 14.9 Non-linear classifier results

    3 Figure 14.9 Non-linear classifier results vs. physicians’ three-category diagnoses. Top: Melafind ® - - resubstitution over training set: 179 (malignant melanoma (MM) plus high-grade dysplastic nevus (HGDN)) and 949 non-MM. Middle: MelaFind - - blind test on 37 MM + HGDN and 440 non-MM. Bottom: ph

Electro Optical Sciences — IPO Roadshow (July 2008) on 6ix